R&D Locations: England, UK

Discovery Park, Sandwich, UK

Pfizer has retained a presence at Discovery Park in Sandwich since exiting the majority of the company's R&D operations from the site during 2011. A number of Pfizer capabilities critical to the delivery of the company's mid to late stage portfolio are located at Discovery Park. These include Pharmaceutical Sciences; Medical Regulatory; Business Units; Quality Assurance; and Business Support Functions (Procurement & Operation, HR, Finance, Patents). As part of the Pharmaceutical Sciences operation, Pfizer's unique pilot plant production and solid and liquid dose manufacturing continue at the site. Pfizer's presence in Cambridge and Discovery Park offers opportunities to collaborate on industry projects and initiatives in the UK and Europe.

Historically the Sandwich site has an excellent track record of discovering new medicines to improve the health and quality of life of people suffering from critical diseases. Some of Pfizer's most important medicines were discovered at Sandwich. They include Celsentri® (maraviroc), the first new oral class of HIV treatment in more than a decade; Revatio® (sildenafil) for the rare condition of Pulmonary Arterial Hypertension (PAH); Diflucan (fluconazole) and Vfend® (voriconazole), two life-saving anti-fungal medicines; Istin (amlodipine) and Cardura (doxazosin), for the treatment of cardiovascular disease; and Viagra® (sildenafil) for erectile dysfunction.

Neusentis, Cambridge, UK

Neusentis was established in April 2011 as a biotech-like unit combining research in pain, sensory disorders, and regenerative medicine. Pfizer has world-leading expertise in the field of sodium channels and scientists at Neusentis apply this knowledge to deliver new medicines across all forms of pain influenced by this mechanism. They also research auditory and visual disorders linked to ion channels, and take forward Pfizer's regenerative medicine portfolio, including the company's first stem cell clinical study, initiated in 2011 for patients with ulcerative colitis. The name, location, and philosophy of Neusentis epitomises the future of drug discovery and development at Pfizer. It represents a team of scientists with endless curiosity and scientific courage working in partnership with academic researchers in Cambridge and around the globe to change the lives of patients suffering from pain, and other diseases and disorders for which there are no therapies or cures.

In November 2011 Neusentis acquired biopharmaceutical company Icagen. Researchers at both units will continue to pursue the novel science being conducted since 2007 when Pfizer formed a collaboration with Icagen for the discovery, development and commercialisation of compounds that modify three ion channels as new potential treatments for pain and related disorders. These ion channels are important in the generation of electrical signals in nerve fibers that mediate the initiation, transmission and sensation of pain. By selectively targeting these ion channels, the companies are seeking to develop effective treatments for serious pain disorders with fewer side effects.

Pfizer's Device Centre of Emphasis, Cambridge, UK

Pfizer's Device Centre of Excellence (DCoE) specialises in the design and development of drug delivery devices, such as injectors or inhalers. The DCoE group based at Cambridge, UK is responsible for the design of new devices, along with the testing and industrialisation. DCoE both develops internally and works with a wide array of external partners to achieve the optimum device design for Pfizer's drug delivery needs.